Zopiclone
Above: molecular structure of zopiclone
Below: 3D representation of the (S)-zopiclone molecule | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌzoʊpɪkloʊn/ ZOH-pik-lohn |
| Trade names | Imovane, Zimovane, Dopareel, others |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Dependence liability | High |
| Addiction liability | High |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 75–80% |
| Protein binding | 52–59% |
| Metabolism | Hepatic through CYP3A4 and CYP2E1 |
| Elimination half-life | ~5 hours (3.5–6.5 hours) ~7–9 hours for 65+ years old |
| Excretion | Urine (80%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.051.018 |
| Chemical and physical data | |
| Formula | C17H17ClN6O3 |
| Molar mass | 388.81 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Zopiclone, sold under the brand name Imovane among others, is a benzodiazepine-like drug (Z-drug) used as a pharmaceutical treatment for insomnia. While molecularly distinct from benzodiazepine drugs, zopiclone's mechanism of action is similar: it increases the transmission of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, via positive allosteric modulation at GABAA neurons. Zopiclone is considered a sedative and CNS depressant. Zopiclone and other benzodiazepine-like drugs like zaleplon and zolpidem are addictive. Within days to weeks, the body can become accustomed to the effects of zopiclone. The risk of developing tolerance with benzodiazepine-like drugs is comparable to benzodiazepines. When the dose is then reduced or the drug is abruptly stopped, withdrawal symptoms similar to those of benzodiazepine withdrawal may result.
Benzodiazepine-like drugs decrease sleep latency by 10 to 20 minutes. However, no benzodiazepine-like drug has shown clinically significant increase in total sleep time. Zopiclone is recommended only to be taken at the lowest effective dose, with a duration of 2–3 weeks, for short-term insomnia. Use of zopiclone more than 4 weeks is not recommended. It is dangerous to take with benzodiazepines, sedatives, alcohol or other drugs affecting the central nervous system.
In the United States, zopiclone is not commercially available, although its active stereoisomer, eszopiclone, is. Zopiclone is a controlled substance in the United States, Japan, Brazil, New Zealand and some European countries, and may be illegal to possess without a prescription.